CR1 and the “Vanishing Amyloid” Hypothesis of Alzheimer’s Disease

Department of Psychiatry and Alzheimer's Disease Research Center
Biological psychiatry (Impact Factor: 10.26). 03/2013; 73(5):393-5. DOI: 10.1016/j.biopsych.2013.01.013
Source: PubMed
Download full-text


Available from: Sam Gandy, Sep 24, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite compelling genetic evidence indicating that cerebral amyloidosis can, at least sometimes, be the primary cause of Alzheimer’s disease, clinical trials for symptomatic Alzheimer’s disease with amyloid-reducing agents have failed to cause clinical benefit despite succeeding at target engagement. In a landmark shift, the FDA now proposes to approve prophylaxis that alters the trajectory of what is now believed to be typical Alzheimer’s biomarker evolution. The first prevention trials are now beginning in patients with genetic guarantees for or high genetic risks for Alzheimer’s disease. The expectation is that clues to their outcomes will begin to emerge from these trials around 2018. In the meantime, new strategies point to non-neuronal cells and to system pathology. A review of the current state of the art of Alzheimer’s science follows herein.
    Biological psychiatry 01/2013; 75(7). DOI:10.1016/j.biopsych.2013.11.019 · 10.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Humans and other higher primates are unique among mammals in using complement receptor 1 (CR1, CD35) on red blood cells (RBC) to ligate complement-tagged inflammatory particles (immune complexes, apoptotic/necrotic debris, and microbes) in the circulation for quiet transport to the sinusoids of spleen and liver where resident macrophages remove the particles, but allow the RBC to return unharmed to the circulation. This process is called immune-adherence clearance (IAC). In this study we found using luminometric- and fluorescence-based methods, that ligation of CR1 on human RBC promotes ATP release. Our data show that CR1-mediated ATP release does not depend on Ca2+ or enzymes previously shown to mediate an increase in membrane deformability promoted by CR1 ligation. Furthermore, ATP release following CR1 ligation, increases the mobility of the lipid fraction of RBC membranes, which in turn facilitates CR1 clustering, and thereby enhances the binding avidity of complement-opsonized particles to the RBC CR1. Finally, we have found that RBC-derived ATP has a stimulatory effect on phagocytosis of immune-adherent immune complexes.
    Journal of Biological Chemistry 09/2013; 288(43). DOI:10.1074/jbc.M113.486035 · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease is a brain disease that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. It begins slowly and gets worse over time. The main risk factor for Alzheimer's disease is increased age. As a population ages, the frequency of Alzheimer's disease continues to increase. Currently, there is no cure. There are many compromises in the brain of an Alzheimer's patient. Essentially, three modifications occur: decrease of cholinergic impulse, increased toxic effects caused by ROS, and an inflammatory process in which amyloid plaque participates. This study is a mini-review of Alzheimer's disease, and we report advances in the studies concerning enzymes, and substances or targets of these three processes. Our review was focused on a few biological pathways and involved in the pathophysiology of AD: cholinergic system; oxidative stress; beta-amyloid processing; insulin signaling. We analyzed a large body of evidence coming from biochemical studies and a series of compounds which act on these pathways as alternative treatments for the disease.
    Letters in Drug Design &amp Discovery 12/2013; 11(2). DOI:10.2174/15701808113109990063 · 0.77 Impact Factor
Show more